SAN FRANCISCO—To help rheumatologists better understand the underlying mechanisms of autoimmune diseases, Mark Anderson, MD, PhD, professor of adult endocrinology, University of California, San Francisco, spoke during the 2015 ACR/ARHP Annual Meeting on ways in which immune regulation and tolerance work to ensure health in individuals who maintain tolerance to self-antigens and how these processes…
BASEL (Reuters)—A regulatory backlog in developing countries including China has created wait times for drugs awaiting approval of up to seven years, Roche Holding AG Chief Executive Severin Schwan said on Tuesday. “Unfortunately, time lines are getting longer and longer in countries like China,” Schwan said at an oncology event at the Swiss company’s headquarters…
WASHINGTON (Reuters)—The U.S. Food and Drug Administration proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts. The FDA said its draft guidance is designed to prevent the inadvertent substitution of non-interchangeable products and to make it easier to monitor and track usage once…
Maintain compliance with updated federal rules governing privacy protection for patient health information
Key leaders, committee members who can influence federal issues relevant to rheumatology
As state legislatures reconvene, the ACR is identifying states, collaborative partners to help pursue legislation
The ACR/ARHP three-day program at 2014 Annual Meeting in Boston to focus on medical coding updates, compliance rules, federal regulations
What rheumatologists should know about complying with the PPSA when it goes into effect on August 1
New final rule delays Stage 2 and makes changes to Stage 1
The federal act mandates transparency within physician–industry relationship